A retrospective analysis of myeloma patients with extramedullary disease provided insights into the characteristics that may influence outcomes.
Patients with lymphoma or myeloma were assessed prior to and 1 month after initiating chemotherapy for depressive symptoms.
In this retrospective study, researchers investigated whether assessing left ventricular diastolic function in patients receiving carfilzomib for relapsed or refractory multiple myeloma improved risk of cardiovascular adverse events.
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The rate of 5-year overall survival in patients with myelodysplastic syndrome who underwent second allogeneic hematopoietic stem cell transplantation was 25.3%.
Median overall survival was 3.6 years for patients who received upfront therapy and 4.2 years for patients who did not.
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Patients with relapsed multiple myeloma experiencing CVAEs had inferior survival.
In a review published in the June 1 issue of The Lancet Oncology, recommendations are presented for use of newer imaging techniques for the diagnosis of multiple myeloma.
Several different models were found to be equally useful for predicting those at risk of progression in multiple myeloma.
A prospective study sought to determine the antibody response of pneumococcal vaccines in patients with multiple myeloma.
This is the first phase 3 to evaluate daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma.
This is the first phase 3 study evaluating the efficacy of adding a CD38 antibody to pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Chromosomal abnormalities and serum lactate dehydrogenase level are factors included in the revised international staging system (R-ISS) for multiple myeloma.
The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.
For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death.
Lenalidomide reduced the risk of disease progression in patients with intermediate- or high-risk smoldering multiple myeloma, but discontinuation rates were high.
Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
A retrospective study compared disease progression and mortality rates in younger patients with MPNs vs historical controls of older patients with MPNs.
This case illustrates the role of PET/CT imaging at diagnosis in determining extramedullary disease in patients with multiple myeloma.